{"disease":{"id":"ovarian-cancer-peritoneal-neoplasms","name":"ovarian cancer peritoneal neoplasms"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06223763","title":"SUROVA - Surgery in Ovarian Cancer, Comparing Primary and Interval Cytoreductive Surgery","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"Clinica Universidad de Navarra, Universidad de Navarra","has_results":false},{"nct_id":"NCT03740165","title":"Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1367,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03038100","title":"A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1301,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT04498117","title":"Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":615,"lead_sponsor_name":"CanariaBio Inc.","has_results":false},{"nct_id":"NCT03593681","title":"Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy","phase":"","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Boston Scientific Corporation","has_results":true},{"nct_id":"NCT01788995","title":"BOVARI: A Non-Interventional Study of Avastin (Bevacizumab) as Front-Line Treatment in Patients With Ovarian Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":63,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT02571725","title":"PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"New Mexico Cancer Research Alliance","has_results":false},{"nct_id":"NCT00317772","title":"Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT01681368","title":"Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}